HopeStage
Back to overview

ADHD studies

Topics
More filters

ADHD

Attention-deficit/hyperactivity disorder (ADHD) involves persistent difficulties with attention, impulsivity or restlessness that can affect everyday life.

1811studies shown
Showing 553-564 of 1,811
Drug study icon
CompletedNCT00291070

Effects of L-Theanine in Boys With ADHD

Official study title

A Double Blind, Randomized Placebo Controlled Clinical Trial Examining the Effects of L-Theanine (Suntheanine®) in Male Child Subjects With Attention Deficit Hyperactivity Disorder

This study has finished and is no longer accepting participants.

In Coquitlam
ADHDMedication studyAges 8–12
Countries
Canada
Sponsor
University of British Columbia
Drug study icon
CompletedNCT00409708

Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)

Official study title

An Open-label, Behavioral-treatment-controlled Evaluation of the Effects of Extended Release Methylphenidate on the Frequency of Cytogenetic Abnormalities in Children 6 - 12 Years of Age With Attention Deficit Hyperactivity Disorder (ADHD)

This study has finished and is no longer accepting participants.

In Houston
ADHDMedication studyAges 6–12
Countries
United States
Sponsor
Novartis
Drug study icon
CompletedNCT00191945

Atomoxetine for ADHD

Official study title

A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 Weeks in Newly Diagnosed Children and Adolescents Outpatients With Attention-Deficit/Hyperactivity Disorder

This study has finished and is no longer accepting participants.

Multiple locations, including Badajoz
ADHDMedication studyAges 6–15
Countries
Spain
Sponsor
Eli Lilly and Company
Drug study icon
CompletedNCT00776009

Dex-Methylphenidate Extended Release 30 mg Versus 20 mg for ADHD

Official study title

A Randomized, Multi-center, Double-blind, Placebo-controlled, Cross-over Study Evaluating the Safety and Efficacy of Dex-Methylphenidate Extended Release 30 mg vs. 20 mg as Measured by SKAMP-Combined Scores in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
ADHDMedication studyAges 6–12
Countries
United States
Sponsor
Novartis Pharmaceuticals
Drug study icon
CompletedNCT00318448

Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

Official study title

Efficacy, Safety and Tolerability of Zolpidem in the Treatment of Children Aged 6 to 17 Years With ADHD-Associated Insomnia. A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study

This study has finished and is no longer accepting participants.

Multiple locations, including Bridgewater
ADHDMedication studyAges 6–17
Countries
United States, Canada
Sponsor
Sanofi

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.